Neuropharmacology and Clinical Relevance of Ssris In Anxiety Disorders: From Molecular Targets to Therapeutic Strategies

Background: Selective serotonin reuptake inhibitors represent the cornerstone of pharmacological treatment for anxiety disorders, offering symptom relief through the modulation of serotonergic pathways. Their efficacy in conditions such as generalised anxiety disorder, panic disorder, and social anxiety disorder has established them as first-line therapies. However, a deeper understanding of their pharmacodynamics and clinical outcomes is critical for optimizing therapeutic strategies. Objective: This review aims to analyse the mechanisms underlying the pharmacological actions of SSRIs, assess their clinical efficacy and safety profiles in anxiety disorders, and explore emerging trends and future directions in SSRI development. Methods: A systematic literature review was conducted following PRISMA guidelines. Databases such as PubMed, Scopus, and Cochrane Library were searched using keywords including "SSRIs," "anxiety disorders," "mechanisms," and "efficacy." Articles published in English focusing on clinical trials, meta-analyses, and mechanistic studies were included. Results: SSRIs exert their therapeutic effects primarily by increasing serotonin availability in the synaptic cleft, enhancing downstream serotonergic signalling. Evidence supports their efficacy in alleviating anxiety symptoms across diverse populations, with improvements in quality of life. Commonly prescribed SSRIs such as sertraline, escitalopram, and paroxetine demonstrate favourable benefit-risk profiles, although adverse effects like gastrointestinal disturbances and sexual dysfunction are prevalent. Conclusion: SSRIs remain essential in the management of anxiety disorders, demonstrating consistent therapeutic benefits. However, challenges such as treatment-resistant cases and adverse effects necessitate further exploration. Future research should prioritize individualized treatment approaches, biomarker identification, and novel pharmacological combinations to advance therapeutic outcomes.